• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

hsa_circ_0007534 的过表达预示着骨肉瘤的预后不良,并通过影响 AKT/GSK-3β 信号通路来调节细胞生长和凋亡。

Overexpression of hsa_circ_0007534 predicts unfavorable prognosis for osteosarcoma and regulates cell growth and apoptosis by affecting AKT/GSK-3β signaling pathway.

机构信息

Department of Orthopedics Surgery, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, 161000, China.

Department of Orthopedics Surgery, The Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, 161000, China.

出版信息

Biomed Pharmacother. 2018 Nov;107:860-866. doi: 10.1016/j.biopha.2018.08.086. Epub 2018 Aug 22.

DOI:10.1016/j.biopha.2018.08.086
PMID:30142548
Abstract

Accumulating evidence demonstrated the pivotal roles of circular RNAs (circRNAs) in several types of cancers. However, the study relevant to the biological functions of circRNAs in osteosarcoma (OS) is still very limited. Recently, hsa_circ_0007534 has been proved to play key roles in colorectal carcinoma and glioma. In this study, qRT-PCR was used to determine hsa_circ_0007534 expression in OS tissues and cells. The clinical value of hsa_circ_0007534 was further explored. Additionally, cell growth, clone formation ability and cell apoptosis were assessed after hsa_circ_0007534 silenced. The xenograft study was further induced to investigate the roles of hsa_circ_0007534 in vivo. Moreover, AKT/GSK-3β pathway was measured to illustrate the mechanism of hsa_circ_0007534 exerts in OS progression. The data demonstrated that hsa_circ_0007534 is overexpressed in OS tissue samples and cells and this up-regulation is related with larger tumor size and poorer differentiation degree. Moreover, hsa_circ_0007534 is a dismal prognostic biomarker for OS patients. For the functional assays, knockdown of hsa_circ_0007534 suppresses OS cell growth in vitro and in vivo. In addition, hsa_circ_0007534 protects against cell apoptosis via Bcl-2/caspase-3 pathway. Furthermore, AKT/GSK-3β pathway could be activated by hsa_circ_0007534 to facilitate OS progression. In summary, hsa_circ_0007534 may be a rational predictive marker and therapeutic target for OS.

摘要

越来越多的证据表明,环状 RNA(circRNA)在多种类型的癌症中起着关键作用。然而,关于环状 RNA 在骨肉瘤(OS)中的生物学功能的研究仍然非常有限。最近,hsa_circ_0007534 已被证明在结直肠癌和神经胶质瘤中发挥关键作用。在本研究中,使用 qRT-PCR 来确定 OS 组织和细胞中 hsa_circ_0007534 的表达。进一步探讨了 hsa_circ_0007534 的临床价值。此外,在沉默 hsa_circ_0007534 后评估细胞生长、克隆形成能力和细胞凋亡。进一步诱导异种移植研究以研究 hsa_circ_0007534 在体内的作用。此外,测量 AKT/GSK-3β 通路以说明 hsa_circ_0007534 在 OS 进展中发挥作用的机制。数据表明,hsa_circ_0007534 在 OS 组织样本和细胞中过度表达,这种上调与更大的肿瘤大小和更差的分化程度有关。此外,hsa_circ_0007534 是 OS 患者预后不良的生物标志物。对于功能测定,敲低 hsa_circ_0007534 可抑制 OS 细胞在体外和体内的生长。此外,hsa_circ_0007534 通过 Bcl-2/caspase-3 通路保护细胞免受凋亡。此外,hsa_circ_0007534 可激活 AKT/GSK-3β 通路以促进 OS 进展。总之,hsa_circ_0007534 可能是 OS 的合理预测标志物和治疗靶点。

相似文献

1
Overexpression of hsa_circ_0007534 predicts unfavorable prognosis for osteosarcoma and regulates cell growth and apoptosis by affecting AKT/GSK-3β signaling pathway.hsa_circ_0007534 的过表达预示着骨肉瘤的预后不良,并通过影响 AKT/GSK-3β 信号通路来调节细胞生长和凋亡。
Biomed Pharmacother. 2018 Nov;107:860-866. doi: 10.1016/j.biopha.2018.08.086. Epub 2018 Aug 22.
2
Downregulation of circular RNA hsa_circ_0001649 indicates poor prognosis for retinoblastoma and regulates cell proliferation and apoptosis via AKT/mTOR signaling pathway.环状 RNA hsa_circ_0001649 的下调预示着视网膜母细胞瘤的预后不良,并通过 AKT/mTOR 信号通路调节细胞增殖和凋亡。
Biomed Pharmacother. 2018 Sep;105:326-333. doi: 10.1016/j.biopha.2018.05.141. Epub 2018 Jun 1.
3
Overexpressing circular RNA hsa_circ_0002052 impairs osteosarcoma progression via inhibiting Wnt/β-catenin pathway by regulating miR-1205/APC2 axis.环状 RNA hsa_circ_0002052 过表达通过调节 miR-1205/APC2 轴抑制 Wnt/β-catenin 通路抑制骨肉瘤进展。
Biochem Biophys Res Commun. 2018 Aug 25;502(4):465-471. doi: 10.1016/j.bbrc.2018.05.184. Epub 2018 Jun 5.
4
Overexpression of hsa_circ_0136666 predicts poor prognosis and initiates osteosarcoma tumorigenesis through miR-593-3p/ZEB2 pathway.hsa_circ_0136666 的过表达预示着预后不良,并通过 miR-593-3p/ZEB2 通路引发骨肉瘤的肿瘤发生。
Aging (Albany NY). 2020 May 18;12(11):10488-10496. doi: 10.18632/aging.103273.
5
Hsa_circ_0009910 promotes carcinogenesis by promoting the expression of miR-449a target IL6R in osteosarcoma.Hsa_circ_0009910通过促进骨肉瘤中miR-449a的靶标IL6R的表达来促进肿瘤发生。
Biochem Biophys Res Commun. 2018 Jan 1;495(1):189-196. doi: 10.1016/j.bbrc.2017.11.028. Epub 2017 Nov 5.
6
Circular RNA hsa_circ_0001564 regulates osteosarcoma proliferation and apoptosis by acting miRNA sponge.环状RNA hsa_circ_0001564通过充当微小RNA海绵来调节骨肉瘤的增殖和凋亡。
Biochem Biophys Res Commun. 2018 Jan 15;495(3):2369-2375. doi: 10.1016/j.bbrc.2017.12.050. Epub 2017 Dec 9.
7
Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.Hsa_circ_001569 是一个不利的预后因素,通过调节乳腺癌中的 PI3K-AKT 通路促进细胞增殖和转移。
Cancer Biomark. 2019;25(2):193-201. doi: 10.3233/CBM-182293.
8
Circular RNAs hsa_circ_0032462, hsa_circ_0028173, hsa_circ_0005909 are predicted to promote CADM1 expression by functioning as miRNAs sponge in human osteosarcoma.环状 RNA hsa_circ_0032462、hsa_circ_0028173、hsa_circ_0005909 被预测通过作为 miRNA 海绵在人骨肉瘤中发挥作用来促进 CADM1 的表达。
PLoS One. 2018 Aug 28;13(8):e0202896. doi: 10.1371/journal.pone.0202896. eCollection 2018.
9
Decreased circular RNA hsa_circ_0001649 predicts unfavorable prognosis in glioma and exerts oncogenic properties in vitro and in vivo.环状 RNA hsa_circ_0001649 表达下调预示着胶质瘤患者预后不良,并在体外和体内发挥致癌作用。
Gene. 2018 Nov 15;676:117-122. doi: 10.1016/j.gene.2018.07.037. Epub 2018 Jul 17.
10
Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT/GSK-3β/β-catenin signaling.热休克蛋白 90 对 Runx2 的转录调控通过 AKT/GSK-3β/β-连环蛋白信号通路控制骨肉瘤细胞凋亡。
J Cell Biochem. 2018 Jan;119(1):948-959. doi: 10.1002/jcb.26260. Epub 2017 Aug 23.

引用本文的文献

1
Circular RNAs in human diseases.人类疾病中的环状RNA
MedComm (2020). 2024 Sep 4;5(9):e699. doi: 10.1002/mco2.699. eCollection 2024 Sep.
2
Interaction of ncRNAs and the PI3K/AKT/mTOR pathway: Implications for osteosarcoma.非编码RNA与PI3K/AKT/mTOR信号通路的相互作用:对骨肉瘤的影响
Open Life Sci. 2024 Aug 6;19(1):20220936. doi: 10.1515/biol-2022-0936. eCollection 2024.
3
Circular RNAs: implications of signaling pathways and bioinformatics in human cancer.环状 RNA:信号通路和生物信息学在人类癌症中的意义。
Cancer Biol Med. 2023 Mar 2;20(2):104-28. doi: 10.20892/j.issn.2095-3941.2022.0466.
4
Hsa_circ_0005050 regulated the progression of oral squamous cell carcinoma via miR-487a-3p/CHSY1 axis.Hsa_circ_0005050通过miR-487a-3p/CHSY1轴调控口腔鳞状细胞癌的进展。
J Dent Sci. 2023 Jan;18(1):282-294. doi: 10.1016/j.jds.2022.05.012. Epub 2022 Jun 4.
5
promotes proliferation and invasion in colorectal cancer and epithelial-mesenchymal transition.促进结直肠癌的增殖、侵袭及上皮-间质转化。
J Gastrointest Oncol. 2022 Dec;13(6):3090-3099. doi: 10.21037/jgo-22-1176.
6
Circ_0007534 as new emerging target in cancer: Biological functions and molecular interactions.环状RNA_0007534作为癌症新出现的靶点:生物学功能与分子相互作用
Front Oncol. 2022 Nov 24;12:1031802. doi: 10.3389/fonc.2022.1031802. eCollection 2022.
7
Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.免疫抑制细胞与非编码 RNA 的调控作为骨肉瘤的免疫治疗策略。
Front Immunol. 2022 Nov 15;13:1025532. doi: 10.3389/fimmu.2022.1025532. eCollection 2022.
8
Non-coding RNAs as potential biomarkers in osteosarcoma.非编码RNA作为骨肉瘤潜在的生物标志物
Front Genet. 2022 Oct 19;13:1028477. doi: 10.3389/fgene.2022.1028477. eCollection 2022.
9
CircAGFG1 Promotes Osteosarcoma Progression and Stemness by Competing with miR-302a-3p to Upregulate the Expression of LATS2.环状AGFG1通过与miR-302a-3p竞争上调LATS2的表达来促进骨肉瘤进展和干性。
Evid Based Complement Alternat Med. 2022 Jul 31;2022:6370766. doi: 10.1155/2022/6370766. eCollection 2022.
10
Dissecting the Role of Circular RNAs in Sarcomas with Emphasis on Osteosarcomas.剖析环状RNA在肉瘤中的作用,重点关注骨肉瘤
Biomedicines. 2021 Nov 8;9(11):1642. doi: 10.3390/biomedicines9111642.